Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epit...Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epithelial cancer in The Third Affiliated Hospital of SUN Yat-sen University(Guangzhou, China) from June 2010 to June 2013, were randomly divided into the study group and the control group. The study group contained 18 cases using Shenqi Fuzheng injection combined with TP(Taxol + Carboplatin/cisplatin) chemotherapy, and the control group contained 18 cases only using TP chemotherapy without Shenqi Fuzheng injection. During and after chemotherapy, the side-effects and therapy effects were observed. Results: The grade II of nausea and vomit were less in the study group than that in the control group, which was significantly different(P < 0.05). But there were no significantly differences in grade I of nausea and vomit between the two groups(P > 0.05). There was less degree of decrease of lymphocyte in the study group than that in the control group, which was significantly different(P < 0.05). But between two groups, there were no significant differences in the drop of white blood cells and red blood cells, the incidence of allergic reaction, liver and renal functions, nerve lesion and phalacrosis(P > 0.05). There was no significant difference in chemotherapy effect between the two groups(P > 0.05). Conclusion: Shenqi Fuzheng injection can in some degree relieve the side effects of TP chemotherapy for the patients with ovarian epithelial cancer, including relieving nausea and vomiting, protecting lymphocytes, and has no conflict effect on chemotherapy efficacy.展开更多
In comparison with the normal people group, values of blood CD<sub>2</sub><sup>+</sup> and CD<sub>4</sub><sup>+</sup> in pa-tients with mallgnant tumors treated with rad...In comparison with the normal people group, values of blood CD<sub>2</sub><sup>+</sup> and CD<sub>4</sub><sup>+</sup> in pa-tients with mallgnant tumors treated with radiotherapy and chemotherapy were significantly lower andthe ratio of CD<sub>助</sub><sup>+</sup> and CD<sub>8</sub><sup>+</sup> decreased obviously （all P【0.001）; CD<sub>8</sub><sup>+</sup> had no apparent change （P】0.05）. Following acupunctural treatment, values of CD<sub>2</sub><sup>+</sup>,CD<sub>4</sub><sup>+</sup> and the ratio of CD<sub>4</sub><sup>+</sup> to CD<sub>8</sub><sup>+</sup> increasedobviously （all P【0.001）; while those of the medicinal control group had no significant change aftertreatment（P】0. 05）. Values of IgG, IgA and IgM in patients’ serum presented an abnormal de-creasing or increasing tendency, and C<sub>3</sub> in minority of patients were raised. Results indicated thatthere was a biphasic regulatory effect of acupuncture on the disturbance of humoral immunity andcould correct the deviation of C<sub>3</sub> level; and its effect was better than or similar to that of the medicinecontrol group. It demonstrates that acupuncture can enhance and regulate. the immune function of pa-tients treated with radiotherapy展开更多
Chemotherapy-induced diarrhea(CID)is a common and often severe side effect experienced by colorectal cancer(CRC)patients during their treatment.As chemotherapy regimens evolve to include more efficacious agents,CID is...Chemotherapy-induced diarrhea(CID)is a common and often severe side effect experienced by colorectal cancer(CRC)patients during their treatment.As chemotherapy regimens evolve to include more efficacious agents,CID is increasingly becoming a major cause of dose limiting toxicity and merits further investigation.Inflammation is a key factor behind gastrointestinal(GI)toxicity of chemotherapy.Different chemotherapeutic agents activate a diverse range of pro-inflammatory pathways culminating in distinct histopathological changes in the small intestine and colonic mucosa.Here we review the current understanding of the mechanisms behind GI toxicity and the mucositis associated with systemic treatment of CRC.Insights into the inflammatory response activated during this process gained from various models of GI toxicity are discussed.The inflammatory processes contributing to the GI toxicity of chemotherapeutic agents are increasingly being recognised as having an important role in the development of anti-tumor immunity,thus conferring added benefit against tumor recurrence and improving patient survival.We review the basic mechanisms involved in the promotion of immunogenic cell death and its relevance in the treatment of colorectal cancer.Finally,the impact of CID on patient outcomes and therapeutic strategies to prevent or minimise the effect of GI toxicity and mucositis are discussed.展开更多
目的探讨刺梨提取物CL联合苦参碱(m atrine)抑制人胃癌细胞SGC-7901培养上清诱导的人脐静脉内皮细胞ECV-304的增殖和凋亡及其机制。方法人胃癌细胞SGC-7901培养上清诱导培养人脐静脉内皮细胞ECV-304,多个质量浓度苦参碱、CL单药干预,或...目的探讨刺梨提取物CL联合苦参碱(m atrine)抑制人胃癌细胞SGC-7901培养上清诱导的人脐静脉内皮细胞ECV-304的增殖和凋亡及其机制。方法人胃癌细胞SGC-7901培养上清诱导培养人脐静脉内皮细胞ECV-304,多个质量浓度苦参碱、CL单药干预,或多个质量浓度苦参碱联合CL干预,M TT法检测内皮细胞增殖抑制率,中效原理法判断联合用药的相互作用;采用RT-PCR和蛋白印迹法分析K i-67、B ax、B cl-2 mRNA/蛋白表达变化。结果10 m g/L、20 m g/L、40 m g/L、80 m g/L、160 m g/L质量浓度的CL干预48小时,其抑制率分别为(15.1±2.1)%、(23.1±2.3)%、(34.1±3.3)%、(46.9±3.8)%、(68.8±2.9)%;15 m g/L、30 m g/L、60 m g/L、120 m g/L、240 m g/L质量浓度的苦参碱干预48小时,ECV-304抑制率分别为(20.8±1.3)%、(25.1±2.2)%、(40.9±1.1)%、(62.9±2.2)%、(77.2±1.9)%;CL+苦参碱联合干预48小时,其抑制率分别为(33.8±2.1)%、(46.8±2.4)%、(84.2±2.0)%、(88.1±2.2)%、(94.8±0.9)%,以上均呈剂量依赖(P<0.05)。IC50浓度(75 m g/L)CL、IC50浓度(75 m g/L)苦参碱、1/2 IC50(CL+苦参碱)分别干预ECV-304细胞,抑制率分别为(40.7±1.3)%、(46.2±1.2)%、(51.4±0.7)%,联合用药抑制率增高(P<0.05);中效原理得出一定浓度范围两药联合为协同效应;与单独用药组比较,联合用药组K i-67、B cl-2 mRNA/蛋白表达显著降低,而B ax mRNA/蛋白表达显著增高。结论刺梨提取物CL、苦参碱均可抑制人脐静脉内皮细胞ECV-304的增殖,两药联合应用存在协同作用。展开更多
基金Supported by a grant of Chinese Medicine Scientific Research of Guangdong Province(No.2010113)
文摘Objective: The aim of the study was to observe the clinical effects of Shenqi Fuzheng injection decreasing sideeffects of chemotherapy for patients with ovarian epithelial cancer. Methods: The 36 cases of ovarian epithelial cancer in The Third Affiliated Hospital of SUN Yat-sen University(Guangzhou, China) from June 2010 to June 2013, were randomly divided into the study group and the control group. The study group contained 18 cases using Shenqi Fuzheng injection combined with TP(Taxol + Carboplatin/cisplatin) chemotherapy, and the control group contained 18 cases only using TP chemotherapy without Shenqi Fuzheng injection. During and after chemotherapy, the side-effects and therapy effects were observed. Results: The grade II of nausea and vomit were less in the study group than that in the control group, which was significantly different(P < 0.05). But there were no significantly differences in grade I of nausea and vomit between the two groups(P > 0.05). There was less degree of decrease of lymphocyte in the study group than that in the control group, which was significantly different(P < 0.05). But between two groups, there were no significant differences in the drop of white blood cells and red blood cells, the incidence of allergic reaction, liver and renal functions, nerve lesion and phalacrosis(P > 0.05). There was no significant difference in chemotherapy effect between the two groups(P > 0.05). Conclusion: Shenqi Fuzheng injection can in some degree relieve the side effects of TP chemotherapy for the patients with ovarian epithelial cancer, including relieving nausea and vomiting, protecting lymphocytes, and has no conflict effect on chemotherapy efficacy.
文摘In comparison with the normal people group, values of blood CD<sub>2</sub><sup>+</sup> and CD<sub>4</sub><sup>+</sup> in pa-tients with mallgnant tumors treated with radiotherapy and chemotherapy were significantly lower andthe ratio of CD<sub>助</sub><sup>+</sup> and CD<sub>8</sub><sup>+</sup> decreased obviously （all P【0.001）; CD<sub>8</sub><sup>+</sup> had no apparent change （P】0.05）. Following acupunctural treatment, values of CD<sub>2</sub><sup>+</sup>,CD<sub>4</sub><sup>+</sup> and the ratio of CD<sub>4</sub><sup>+</sup> to CD<sub>8</sub><sup>+</sup> increasedobviously （all P【0.001）; while those of the medicinal control group had no significant change aftertreatment（P】0. 05）. Values of IgG, IgA and IgM in patients’ serum presented an abnormal de-creasing or increasing tendency, and C<sub>3</sub> in minority of patients were raised. Results indicated thatthere was a biphasic regulatory effect of acupuncture on the disturbance of humoral immunity andcould correct the deviation of C<sub>3</sub> level; and its effect was better than or similar to that of the medicinecontrol group. It demonstrates that acupuncture can enhance and regulate. the immune function of pa-tients treated with radiotherapy
基金Supported by A Newman Fellowship awarded by the University College Dublin Foundation and sponsored by Helsinn-Birex Pharmaceuticals
文摘Chemotherapy-induced diarrhea(CID)is a common and often severe side effect experienced by colorectal cancer(CRC)patients during their treatment.As chemotherapy regimens evolve to include more efficacious agents,CID is increasingly becoming a major cause of dose limiting toxicity and merits further investigation.Inflammation is a key factor behind gastrointestinal(GI)toxicity of chemotherapy.Different chemotherapeutic agents activate a diverse range of pro-inflammatory pathways culminating in distinct histopathological changes in the small intestine and colonic mucosa.Here we review the current understanding of the mechanisms behind GI toxicity and the mucositis associated with systemic treatment of CRC.Insights into the inflammatory response activated during this process gained from various models of GI toxicity are discussed.The inflammatory processes contributing to the GI toxicity of chemotherapeutic agents are increasingly being recognised as having an important role in the development of anti-tumor immunity,thus conferring added benefit against tumor recurrence and improving patient survival.We review the basic mechanisms involved in the promotion of immunogenic cell death and its relevance in the treatment of colorectal cancer.Finally,the impact of CID on patient outcomes and therapeutic strategies to prevent or minimise the effect of GI toxicity and mucositis are discussed.
文摘目的探讨刺梨提取物CL联合苦参碱(m atrine)抑制人胃癌细胞SGC-7901培养上清诱导的人脐静脉内皮细胞ECV-304的增殖和凋亡及其机制。方法人胃癌细胞SGC-7901培养上清诱导培养人脐静脉内皮细胞ECV-304,多个质量浓度苦参碱、CL单药干预,或多个质量浓度苦参碱联合CL干预,M TT法检测内皮细胞增殖抑制率,中效原理法判断联合用药的相互作用;采用RT-PCR和蛋白印迹法分析K i-67、B ax、B cl-2 mRNA/蛋白表达变化。结果10 m g/L、20 m g/L、40 m g/L、80 m g/L、160 m g/L质量浓度的CL干预48小时,其抑制率分别为(15.1±2.1)%、(23.1±2.3)%、(34.1±3.3)%、(46.9±3.8)%、(68.8±2.9)%;15 m g/L、30 m g/L、60 m g/L、120 m g/L、240 m g/L质量浓度的苦参碱干预48小时,ECV-304抑制率分别为(20.8±1.3)%、(25.1±2.2)%、(40.9±1.1)%、(62.9±2.2)%、(77.2±1.9)%;CL+苦参碱联合干预48小时,其抑制率分别为(33.8±2.1)%、(46.8±2.4)%、(84.2±2.0)%、(88.1±2.2)%、(94.8±0.9)%,以上均呈剂量依赖(P<0.05)。IC50浓度(75 m g/L)CL、IC50浓度(75 m g/L)苦参碱、1/2 IC50(CL+苦参碱)分别干预ECV-304细胞,抑制率分别为(40.7±1.3)%、(46.2±1.2)%、(51.4±0.7)%,联合用药抑制率增高(P<0.05);中效原理得出一定浓度范围两药联合为协同效应;与单独用药组比较,联合用药组K i-67、B cl-2 mRNA/蛋白表达显著降低,而B ax mRNA/蛋白表达显著增高。结论刺梨提取物CL、苦参碱均可抑制人脐静脉内皮细胞ECV-304的增殖,两药联合应用存在协同作用。
